We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use °Ç¸ç³Ô¹Ï, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This professional resource outlines the importance of infection prevention and control and how it can contribute to reducing antimicrobial resistance (AMR).
Up to £55 million is available through the second phase of the RD&D programme to support the development and demonstration of High Temperature Gas Reactor (HTGR) technology in the UK.
Visual maps of the factors that lead to the development of antimicrobial resistance (AMR) and the interaction between them.
BEIS is providing up to £2.5 million in innovation funding to support the development and demonstration of High Temperature Gas Reactor (HTGR) technology in the UK.
The AMR RD&D programme aims to demonstrate high temperature gas reactor (HTGR) technology by the early 2030s, in time for potential commercial AMRs to support net zero by 2050.
Overview of the current situation of antimicrobial resistance (AMR) in bacteria, viruses and fungi that can cause disease in humans.
Details of the 2-phase Advanced Modular Reactor Feasibility and Development Project.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve °Ç¸ç³Ô¹Ï, we’d like to know more about your visit today. .